Status | Study |
Active, not recruiting |
Study Name: Explore the Efficacy and Safety of FMT With Different Bacterial Doses in the Treatment of Hepatic Encephalopathy Condition: Hepatic Encephalopathy Date: 2022-12-14 Interventions: Interventional |
RECRUITING |
Study Name: Efficacy of L-Ornithine L-Aspartate (LOLA) as an Adjunct to Branched Chain Amino Acids (BCAA) Enriched Solutions on Clinical Outcomes in ICU Patients With Hepatic Encephalopathy Condition: Hepatic Encephalopathy Date: 2022-09-07 Interventions: patients will receive branched-chain amino acids (BCAA), enriched solution (Aminoleban) and L-ornithine L-aspartate (LOLA) |
Recruiting |
Study Name: PEG (Polyethylene Glycol)Versus Lactulose For Treatment Of Overt Hepatic Encephalopathy Condition: Hepatic Encephalopathy Date: 2017-03-24 Interventions: Drug: Lactulose (lactulose) (2 |
Not yet recruiting |
Study Name: Low-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy Condition: Covert Hepatic Encephalopathy Date: 2017-01-30 Interventions: Drug: Rifaximin The investigators use low-dose rifaximin for the treatment of patients with covert hepat |
Completed |
Study Name: A Retrospective Study to Assess the Effectiveness and Safety of Lactulose Retention Enema in the Treatment of Cirrhotic Patients With Grade 3 or 4 (West Haven Criteria) Hepatic Encephalopathy (HE) (The RETRO Study) Condition: Hepatic Encephalopathy Date: 2015-02-17 |
Completed |
Study Name: The Effects of Nitazoxanide in Hepatic Encephalopathy Condition: Hepatic Encephalopathy Date: 2015-01-06 Interventions: Drug: Nitazoxanide 500 mg nita |
Recruiting |
Study Name: Fecal Microbiota Transplantation (FMT) in the Management of Hepatic Encephalopathy (HE): a Pilot Study Condition: Hepatic Encephalopathy Date: 2014-08-26 Interventions: Biological: Fecal Microbiota Transplant Fecal transplant processed from routinely screened universal don |
Completed |
Study Name: Lactulose, L-ornithine L-aspartate, or Rifaximin Versus Placebo for Preventing Hepatic Encephalopathy in Variceal Bleeding Condition: Hepatic Encephalopathy Date: 2014-06-04 Interventions: Drug: Lactulose 30 ml by mouth |
Terminated |
Study Name: The Role of Bacterial Overgrowth and Delayed Intestinal Transit in Hepatic Encephalopathy. Condition: Hepatic Encephalopathy Date: 2013-05-01 Interventions: Drug: Rifaximin Participants in Phase B will be administered 550 mg of Rifaximin two times a day for 14 |
Recruiting |
Study Name: Efficacy, Safety, And Pharmacokinetics Of Rifaximin In Subjects With Severe Hepatic Impairment And Hepatic Encephalopathy Condition: Hepatic Encephalopathy Date: 2013-04-24 Interventions: Drug: Placebo Placebo, oral, 0 |